Indikationen/Anwendungsmöglichkeiten: although approved for HIT in several countries other than the United States, it was initially approved to prevent postoperative VTE but is more expensive than LMWHs, so it is no longer marketed in this indication (1).

Eigenschaften/Wirkungen: is a subcutaneous, low-molecular-weight heparinoid with a long half-life that, like LMWH, requires antithrombin to inactivate factor Xa (1).